# SkinBioTherapeutics SBTX signs MTA with global consumer goods company

- Link: https://www.directorstalkinterviews.com/skinbiotherapeutics-sbtx-signs-mta-global-consumer-goods-company/412748661
- Published: 2018-04-03T07:27:50+01:00
- Author: Giles Arbor

**SkinBioTherapeutics plc** (LON:SBTX), a life science company focused on skin health,
announced today the signing of an MTA relating to its proprietary SkinBiotix® technology
with a major, global consumer goods company.

The Company has been speaking to a range of commercial partners interested in evaluating
its SkinBiotix® technology ahead of its human studies which are scheduled to commence
later this year.

Having shared the initial pre-clinical data with a number of interested parties,
one potential partner to date has progressed to an MTA, granting it access to the
SkinBiotix® technology. An MTA is a standard agreement governing the transfer of
material between parties enabling the recipient to assess the technology and, where
the outcome is successful, can be a precursor to future commercial discussions.

The MTA provides for SkinBioTherapeutics to share a sample of its material against
which the third party will conduct its own in-house assessment. Whilst at this stage
there can be no certainty that discussions will progress further than the initial
sharing of the technology, the Company is encouraged by the level of interest that
has been shown in its pre-clinical data.

The Company is initially targeting cosmetic skin care and in this market SkinBioTherapeutics’
skin microbiome technology is unusual in that its properties are supported by scientific
data. These demonstrate its ability to improve the skin barrier, offer protection
from infection and enhance skin repair. These characteristics support potential 
opportunities for the Company in cosmetics, anti-infectives and dermatological indications(
e.g. eczema).

Most recently, the Company reported good results in a variety of toxicity studies
and the development of its formulation as a gel, cream and lotion which will be 
tested to determine the best concentration and application for its humans studies.

> **Dr Cath O’Neill, CEO of SkinBioTherapeutics Plc, commented:** “Whilst these 
> are early discussions, we are encouraged that a company of this calibre wants 
> to look at our technology more closely through an MTA. Even at this early stage
> of its development, we are pleased to see that SkinBiotix® is starting to generate
> a buzz in the skin care industry.”

Share on: